[Cisplatin and derivatives with radiation therapy: for what clinical use?]

Cancer Radiother. 2004 Nov;8 Suppl 1:S88-94.
[Article in French]

Abstract

Since its discovery by Rosenberg in 1965, cisplatin and its derivatives have appeared as the most important chemotherapeutic agents, particularly for their radiosensitizing properties and their clinical use with radiation. In spite of numerous preclinical and clinical studies, optimal schedules of platin and radiotherapy combination have to be defined. The first part of this overview will describe biological mechanisms of interaction between radiation therapy and platinum derivatives. The second part will report the major clinical impact of their association.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Animals
  • Anus Neoplasms / drug therapy
  • Anus Neoplasms / mortality
  • Anus Neoplasms / radiotherapy
  • Carboplatin / administration & dosage
  • Carboplatin / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / radiotherapy
  • Cisplatin / administration & dosage
  • Cisplatin / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Combined Modality Therapy
  • Female
  • Humans
  • Hydroxyurea / administration & dosage
  • Hydroxyurea / therapeutic use
  • Laryngeal Neoplasms / drug therapy
  • Laryngeal Neoplasms / radiotherapy
  • Leukemia P388 / drug therapy
  • Leukemia P388 / radiotherapy
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality
  • Lung Neoplasms / radiotherapy
  • Male
  • Mammary Neoplasms, Experimental / drug therapy
  • Mammary Neoplasms, Experimental / radiotherapy
  • Meta-Analysis as Topic
  • Mice
  • Neoplasms / drug therapy*
  • Neoplasms / mortality
  • Neoplasms / radiotherapy*
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / therapeutic use*
  • Oxaliplatin
  • Radiation-Sensitizing Agents / administration & dosage
  • Radiation-Sensitizing Agents / therapeutic use*
  • Radiotherapy Dosage
  • Randomized Controlled Trials as Topic
  • Rats
  • Rectal Neoplasms / drug therapy
  • Rectal Neoplasms / radiotherapy
  • Time Factors
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / radiotherapy
  • Uterine Cervical Neoplasms / drug therapy
  • Uterine Cervical Neoplasms / mortality
  • Uterine Cervical Neoplasms / radiotherapy

Substances

  • Organoplatinum Compounds
  • Radiation-Sensitizing Agents
  • Oxaliplatin
  • Carboplatin
  • Cisplatin
  • Hydroxyurea